Pfizer Inc PFE

$30.11 +0.67 (2.28%)

Valuation

Market cap
167,798,400,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.70
Forward PE
10.04
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
34,442,100
Avg volume
32,564,395
Day's range
$29.59 – $30.25
Shares out
5,699,674,000
Stochastic %K
95%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

TopOptionAlert Oct 21, 5:01 AM
$PFE NOV06 30C · update Called at $29.44 on Oct 19, now $30.11 (+2.3%). The trade is working, with objectives at $31.25, then $33, and the invalidation at $28.55. P.S. Earnings land November 3. Until then the levels above are the whole map, and they do not move.
0 replies
Techdamentals Oct 21, 3:52 AM
$PFE reports on Nov 3, while health care stocks sit at a record high after a 2.4% gain on Tuesday Oct 20. In the June quarter, revenue was $15.0B, up 3%, but it had a net loss of $248M after $4.3B of impairments (write-downs of assets worth less than expected). Debt is about $63.2B against $11.7B in cash and short-term investments. The Techdamentals IV Calculator reads its fundamentals in plain English, from the company's own reported numbers. What do its fundamentals actually say? 👇 https://techdamentals.com/v3/PFE?ref=st Educational, not advice.
0 replies
Honest_Abe Oct 21, 3:47 AM
$SPY $QQQ $PFE $JNJ "Team doctors were initially hopeful that Hurts only had a Johnson & Johnson. Unfortunately, follow-up CT scans today showed it's a full-blown Pfizer, and he will need several months to recover." "Losing blood flow is bad," explained Dr. Vijay Gupta.
0 replies
RocroBio Oct 21, 2:05 AM 0 replies
RocroBio Oct 21, 2:04 AM 0 replies
jrh34 Oct 21, 1:42 AM
$CRDF I said it yesterday and maintain it, a significant move is building ahead of the 22nd. You can sit on the sidelines or you can participate in a decent size trade. $PFE is also one to add to your portfolio ahead of a democrat sweep in the midterms. And one last free tip: buy $SKYD or the warrants. That's all.
0 replies
jrh34 Oct 21, 1:35 AM
$PFE This is one to own ahead of Democrats taking the house and senate. A return to $50 by early next year is all but certain. Pharma will do well with Democrats back in charge. Position accordingly $XBI
0 replies
SellasgpsCurativeBAT11 Oct 20, 11:36 PM
$AZN $BMY $JNJ $PFE $SLS I wrote Extensively about the fact that Sellas Headquarters Lease wasn’t Renewed during early October window like per usual occurrence every past year. A review of SEC filings shows SELLAS has extended its 7 Times Square sublease in one-year increments, each signed approximately 12 months before expiration: - December 11, 2023: extended to September 30, 2025 - October 2-3, 2024: extended to September 30, 2026 (8-K filed October 4) - October 1, 2025: extended to September 30, 2027 (8-K filed October 3) Under this pattern, an extension to September 30, 2028 would have been expected on or about October 1, 2026. As of the close on Friday, October 2, 2026 No filing was made. So BO is a foregone conclusion. I wouldn’t be surprised if we get Data+ deal in the same PR! ✌️🙏❤️‍🩹
0 replies